Categories
Change Password!
Reset Password!
Vaccination plays a critical role in safeguarding cardiovascular health- flu vaccine offers far-reaching benefits beyond flu prevention by reducing severe cardiovascular risks in vulnerable patient populations.
Based on the GRADE (Grading Recommendations Assessment, Development and Evaluation), a novel systematic review delivered compelling evidence regarding the influenza (flu) vaccine that could slash the risk of major cardiovascular events in patients with ischemic heart disease (also called coronary artery disease) to a considerable extent. While it is well-established that influenza can exacerbate cardiovascular conditions, the impact of the flu vaccine on coronary artery disease outcomes has remained unclear—until now.
Five randomized trials involving 5,659 patients with coronary artery disease were included in this review. The data were analyzed from a variety of sources such as PubMed, Cochrane, and Embase.
As revealed, influenza vaccine significantly reduced the risk of major adverse cardiovascular events (MACE), cardiovascular death, all-cause mortality, and myocardial infarction (MI), with risk reductions of 33%, 45%, 42%, and 34%, respectively. Notably, the number needed to treat (NNT) to prevent one adverse event was 37 for MACE, 56 for cardiovascular death, 67 for MI, and 41 for all-cause mortality.
However, no substantial advantages were observed in preventing hospitalization for heart failure or the need for revascularization techniques. Despite this, the evidence for reducing MACE was so robust that future trials on this outcome were deemed unnecessary, ensuring that the influenza vaccine is an important consideration in managing coronary artery disease patients' cardiovascular health.
Travel Medicine and Infectious Disease
Association between influenza vaccination and prognosis in patients with ischemic heart disease: A systematic review and meta-analysis of randomized controlled trials
Xiao Liu et al.
Comments (0)